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Dear Editor,
A 37-year-old man presented to the emergency department 
with symptoms of high fever, polyuria, and polydipsia. A physical 
examination revealed body temperature of 37.8 °C, heart rate of 
118 beats per minute, blood pressure of 95/60 mmHg, and oxygen 
saturation of 97% in room air. The patient had pale conjunctiva. 
He had no past medical history. A detailed recent history showed 
that the patient had unintentional weight loss of 20 pounds in the 
past 1 month.
Laboratory tests revealed low white blood cell count 
(2x103/µL; normal range 4-10x103/µL), low hemoglobin count 
(10.2 g/dL; normal range 14-16 g/dL), elevated C-reactive protein 
level (2.6 mg/dL; normal range 0-0.5 mg/dL), high erythrocyte 
sedimentation rate (80 mm/h; normal range 0-15 mm/h), high 
mean cell volume (132 fL; normal range 80-96 fL), high platelet 
count (603x103/µL; normal range 150-400x103/µL), and elevated 
serum sodium level (157 mEq/L; normal range 135-145 mEq/L). 
The physical examination, clinical history, and laboratory findings 
suggested diabetes insipidus. Hormone analysis showed decreased 
pituitary hormones levels (thyroid-stimulating hormone 0.04 
µIU/mL; normal range 0.2-4.2 µIU/mL, free-T4 0.801 ng/dL; 
normal range 0.99-1.65 ng/dL, cortisol 3.21 ug/dL; normal range 
10-20 ug/dL, adrenocorticotropin 7.3 pg/mL; normal range 8-50 
pg/mL). The clinical and laboratory findings of the patient showed 
panhypopituitarism.
The patient underwent hyponatremic intravenous hydration 
(0.45% saline and 5% dextrose). After this treatment, the 24-
hour urine volume was 6000-7000 cc. A water deprivation 
test demonstrated worsening of hypernatremia. The serum 
osmolality test showed hyperosmolarity with inappropriate 
low urine osmolality. Urinary osmolality was increased two-
fold following vasopressin administration. Nasal 1-deamino-
8-D-arginine vasopressin was started with the diagnosis of 
central diabetes insipidus (CDI). Polydipsia and polyuria were 
improved.
The serum total protein level was decreased (52 g/L; normal 
range 65-85 g/L) and beta-2 microglobulin level was elevated (6.3 
mg/L; normal range <2 mg/L). Serum immunoglobulin levels 
were normal. A smear of bone marrow aspirate showed sheets 
of myeloid cells that accounted for 82% of the overall nucleated 
cell population. Large, bi-nucleate and trinucleate forms were 
noted. Many of these atypical myeloid cells contained small, 
inconspicuous nucleoli. The patient was diagnosed as having acute 
myeloid leukemia (AML). Genetic analysis showed monosomy of 
chromosome 7.
The patient underwent contrast-enhanced cranial magnetic 
resonance imaging (MRI) to investigate the cause of CDI and 
panhypopituitarism. MRI showed hypothalamic hyperintensity 
on fluid attenuation inversion recovery images and contrast 
enhancement on T1-weighted images (Figure 1, 2). 
CDI is an unusual complication of AML and is seen in less than 
1% of patients with AML. The pathogenesis of CDI in patients 
with myeloid leukemia is unclear. It has been reported that CDI 
associated with AML may develop due to different mechanisms 
such as leukemic infiltration, chromosomal abnormalities, 
thrombocytosis, and dysmegakaryopoiesis. Peri pituitary leukemic 
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infiltrations have been shown in postmortem studies in patients 
with AML without clinical CDI (1,2). 
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Figure 1. A) Coronal and B) axial fluid attenuation inversion recovery images shows hyperintensity in hypothalamic areas consistent with edema (white 
arrows)
Figure 2. Contrast-enhanced T1-weighted image shows contrast 
enhancement in hypothalamus (white arrows)
